Ra Pharma’s Cyclomimetic Technology To Help Merck With Difficult Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first partnership, Ra, focused on solutions for intracellular protein-protein reactions, could earn up to $200 million by helping Merck to discover and develop drug candidates for protein targets in several undisclosed therapeutic areas.